SpinLab alumni inContAlert closed its pre-seed funding round with 1.5 Mio. €

Team inContalert MedTech Startup SpinLab Startup inContalert was part of the 14th SpinLab class.

The MedTech startup inContAlert has successfully closed its pre-seed financing round of 1.5 million euros in total. The round is led by High-Tech Gründerfonds, Bayern Kapital, and Carma Fund, accompanied by renowned business angels from the medical technology domain, such as Prof. Dr. Thomas Gottwald, former CEO of Fresenius Biotech and Ovesco AG, Dr. Jörg Stein, former executive at Siemens Healthineers, the British Nialls Foundation, the software entrepreneur Richard Reiber, and the MedTech expert Marcus Irsfeld.

inContAlert's Breakthrough Solution Improves Incontinence Management for Millions

In Germany alone, a staggering 2.2 million individuals could benefit from the groundbreaking technology of inContAlert. This startup has developed a sensor-based solution to enhance the quality of life for those dealing with incontinence. Positioned non-invasively two finger-widths above the pubic bone, the sensor continuously gathers data related to bladder activity. After data collection, this information is analyzed using advanced machine learning and deep learning algorithms. A key component of the solution is a dedicated mobile application, designed to serve as the interface and companion for users. The application offers insights into optimal timings for bladder voiding and delivers timely notifications when a predefined bladder filling level is reached.

inContAlert's technology primarily serves patients dealing with neurogenic bladder disorders, which include conditions such as spinal cord injuries, multiple sclerosis, bladder cancer, or Parkinson’s disease. Looking ahead, this technology could also assist children struggling with bedwetting issues. By emphasizing on-demand emptying, it has the potential to reduce reliance on aids like diapers or catheters, thereby lowering the risk of harm to the urinary tract and kidneys.

The allocated investment will be directed toward conducting further studies, obtaining the CE mark as a medical device, and preparing for market entry.

“Unlike traditional methods of managing incontinence, our technology takes a proactive stance. inContAlert provides an unobtrusive signal preventively, allowing individuals to take action before it’s too late. This approach empowers individuals to regain control over their bladder functions. The encouraging feedback received from patients and medical experts drives ongoing efforts and underscores the demand for innovative solutions in modern and respectful urinary bladder management.” - Dr. Jannik Lockl, CEO & Co-Founder of inContAlert

“The technology underpinning inContAlert is truly fascinating. It reflects the immense commitment, passion, and ‘out-of-the-box’ thinking that the team has dedicated to its creation. The team meets all pivotal prerequisites for establishing a successful enterprise. Their blend of scholarly ingenuity and entrepreneurial pragmatism is exceptional.” - Prof. Dr. Thomas Gottwald, chairman of the advisory board

“inContAlert directly confronts the taboo topic of incontinence. Their technology has the potential to provide daily support to a wide range of patients, helping to improve their quality of life by bringing it closer to what we take for granted. Patients and caregivers regain control over voiding management, contributing to a notable enhancement in the overall quality of care within the healthcare system.” - Jakob Lilienweiss, Investment Analyst at HTGF

“In addition to the positive impacts on the quality of care for incontinence patients, the economic effects achieved through efficient use of medical aids, allocation of personnel, and the prevention of follow-up diseases underscore the overarching value of inContAlert. We are confident that this technology will revolutionize the incontinence market.” - Markus Mrachacz, Managing Partner at Bayern Kapital

“The accomplished founders of inContAlert come with a rich blend of educational backgrounds, collectively encompassing a comprehensive range of crucial skills within the team. Their shared dedication is centered around the transformation of the incontinence market, fueled by profound motivation and unwavering commitment. The inContAlert team distinguishes itself through remarkable ingenuity, a trait that has not only defined their previous accomplishments but also serves as a driving force for their prospective success.” - Christian Leikert, Managing Partner at Carma Fund